Posted 17th December 2018 by Jane Williams
As industry developments continue to improve, the potential for personalised medicine and the possibility of individual diagnosis is on the horizon. These slides, from the Precision Medicine & Biomarkers Leaders Summit: Europe are now available from Andres Hurtado-Lorenzo, Thorsten Gutjahr & Thomas Skot Jensen.
Posted 26th September 2018 by Jane Williams
Immunotherapy continues to gain popularity in several areas related to cancer research and new treatments. Studies prove that each and every cancer case is unique, so the need for personalised medicine presents a logical focus. Personalised cancer vaccines are one form of cancer immunotherapy. The vaccines are a form of precision medicine, which has become an increasingly more enticing area for treatment research.
Failing Blockbuster Medicines, Eroding Operator Margins & Increased Pricing Pressures: What’s Next for Precision Medicine?
Posted 12th September 2018 by Jane Williams
The Precision Medicine and Biomarkers Leaders Summit: Europe takes place this week and in anticipation, we spoke to Unmesh Lal of Frost and Sullivan about his views on what the future holds for precision medicine and how the pharmaceutical industry has changed in recent times.
Posted 5th September 2018 by Jane Williams
I don’t need to tell you that pharma has changed, that it is still changing at speed, or that change is the new normal. I don’t need to tell you because you − more than anyone else − already know. The passing of the blockbuster era has caused uncertainty. Without the superstar drugs of old, where does the industry go next? It’s a serious challenge, but without challenge, there is no change. The answer, of course, is the scalar shift from blockbuster generic to precision medicine specific.
Posted 24th August 2018 by Jane Williams
We spoke to Alex Bastian about how he got started in precision medicine, where he sees it going and how he intends to use real world evidence to unlock the potential around personalised approaches to drug development:
Posted 30th July 2018 by Jane Williams
There has been some interesting news, discoveries and development to catch up on this month in the world of precision medicine. Take a look at the list below to find out more:
Posted 14th May 2018 by Jane Williams
Our understanding of the aberrant biological pathways (oncogenic pathways) that are involved in the formation and progression of cancers has increased with huge leaps in the last decades of cancer research. The ever-increasing knowledge was and still is accompanied by the development of increasing numbers of precision drugs, tailored to neutralize these aberrations.
Posted 30th April 2018 by Jane Williams
Industrial and “omic” scale mutational profiling of solid tumours are possible as a result of massively parallel sequencing technology. However, these clinical genomic testing capabilities have also brought myriad new biological, technical and operational challenges not encountered in monogenic disorder testing. All of this impacts the interpretation and reporting of somatic variants. As a testament to the nascency of this field, the first published consensus guidelines for interpretation of variants in cancer was only released in early 2017.